169 related articles for article (PubMed ID: 7572348)
1. DNA topoisomerase II isozymes involved in anticancer drug action and resistance.
Fernandes DJ; Qiu J; Catapano CV
Adv Enzyme Regul; 1995; 35():265-81. PubMed ID: 7572348
[TBL] [Abstract][Full Text] [Related]
2. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
[TBL] [Abstract][Full Text] [Related]
3. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II cleavable complex formation within DNA loop domains.
Lambert JM; Fernandes DJ
Biochem Pharmacol; 2000 Jul; 60(1):101-9. PubMed ID: 10807951
[TBL] [Abstract][Full Text] [Related]
5. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
Qiu J; Catapano CV; Fernandes DJ
Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
Chen M; Beck WT
Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
Wolverton JS; Danks MK; Granzen B; Beck WT
Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
[TBL] [Abstract][Full Text] [Related]
8. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
Danks MK; Schmidt CA; Deneka DA; Beck WT
Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
[TBL] [Abstract][Full Text] [Related]
9. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
Kim R; Beck WT
Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
[TBL] [Abstract][Full Text] [Related]
10. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
11. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
12. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
[TBL] [Abstract][Full Text] [Related]
13. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
14. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
15. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
16. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
Danks MK; Schmidt CA; Cirtain MC; Suttle DP; Beck WT
Biochemistry; 1988 Nov; 27(24):8861-9. PubMed ID: 2853972
[TBL] [Abstract][Full Text] [Related]
17. Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells.
Fernandes DJ; Smith-Nanni C; Paff MT; Neff TA
Cancer Res; 1988 Apr; 48(7):1850-5. PubMed ID: 3349463
[TBL] [Abstract][Full Text] [Related]
18. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
19. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
20. Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Gromova II; Thomsen B; Razin SV
Proc Natl Acad Sci U S A; 1995 Jan; 92(1):102-6. PubMed ID: 7816796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]